High Purity New England Appoints Chief Scientific Officer
High Purity New England, a supplier of equipment, process systems, and custom solutions for the biopharma industry, has appointed a new chief scientific officer, Dr. Michael Quesenberry.
April 30, 2021
by contractpharma
Everest Medicines Appoints Jennifer Yang as Chief Scientific Officer
Everest Medicines announced today the appointment of Dr. Jennifer Yang as chief scientific officer. Dr. Yang has two decades of leadership experience in drug discovery and development at global pharmaceutical companies.
April 15, 2021
by prnasia
Jubilant Therapeutics Appoints Chief Scientific Officer
Luca Rastelli brings more than 20 years of oncology drug discovery and development experience.
March 10, 2021
by contractpharma
Jubilant Therapeutics appoints Luca Rastelli as Chief Scientific Officer
Dr Rastelli will lead all aspects of R&D for Jubilant Therapeutics and serve as a scientific liaison for the company to investors, partners and the medical community.
March 10, 2021
by expresspharma
Crystal Denlinger Named Chief Scientific Officer for National Comprehensive Cancer Network
The National Comprehensive Cancer Network® (NCCN®)--an alliance of leading cancer centers--announced the appointment of Crystal S. Denlinger, MD, FACP, to the newly-created role of Senior Vice President, Chief Scientific Officer.
January 18, 2021
by prnasia
NeuBase Therapeutics Appoints Chief Scientific Officer
Dr. Curt Bradshaw brings decades of experience in successfully delivering genetic medicines to clinics.
December 3, 2020
by contractpharma
Ascletis appoints new Chief Scientific Officer
Dr. He was a former Global Head of Computational, Biopharmaceutics and Translational PK/PD at Novartis Pharmaceutical Corporation, New Jersey, USA.
October 9, 2019
by biospectrumasia
InMed Pharmaceuticals Announces the Appointment of Dr. Sazzad Hossain, PhD, MSc, as a Member of the Scientific Advisory Board and his Retirement as Chief Scientific Officer
Dr. Hossain stated, "InMed's continued success in developing cannabinoids to treat serious diseases is vital to me. Unfortunately, given recent personal health concerns, I wish to modify my role to that of a scientific advisor.
January 13, 2019
by firstwordpharma
Algenuity appoints new Chief Scientific Officer
Algenuity, a leader in algal biology and industrial biotechnology, is delighted to welcome Dr Alex Pudney to the team as Chief Scientific Officer…
May 22, 2018
by europeanpharmaceuticalreview